|
|
Blood, Vol. 109, Issue 12, 5143-5150, June 15, 2007
Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib: a randomized phase 2 trial
Blood Kantarjian et al.
109: 5143
Supplemental materials for: Kantarjian et al, Vol 109, Issue 12, 5143-5150
In addition to the authors, the following principal investigators also participated in this study:
Argentina: JJ Garcia, I Otero, D Riveros
Australia: C Arthur
Belgium: A Bosly, W Schroyens
Brazil: PE Dorlhiac Llacer, A Moellman Coelho
Canada: D Forrest, C Gambacorti-Passerini, P Laneuville, A Turner
Finland: K Porkka
France: H Dombret, T Facon, F Guilhot, G Marit, M Michalet
Germany: C Bokemeyer, A Hochhaus, D Niederwieser
Israel: A Nagler
Korea: DW Kim
Norway: H Hjorth-Hansen
Peru: L Casanova, J Navarro
Philippines: P Caguioa
Poland: A Dmoszynska, W Jedrzejczak
Puerto Rico: F Cabanillas
South Africa: J Lombard, P Ruff
Sweden: L Stenke, M Varik, H Wadenvik
Taiwan: LY Shih
United Kingdom: J Apperley, T Holyoake
United States of America: J Dispersio, JK Giguere, R Lloyd, J McGurk, MS Murali, S O’Brien, RM Stone
Molecular biology:
Australia: S Branford
Germany: P Erben, M Müller.
|
|
